RAXENTIS
Live / Applied — First extension granted (statement of use) (as of 02 Mar 2026)
What this means for you
Not registered yet, but its 05 May 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99169722
- Mark type
- Stylized text
- Filed
- 05 May 2025
- Published for opposition
- 05 Aug 2025
- Attorney of record
- Anthony P. Venturino
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of muscular dystrophy, muscle wasting, atrophy, neuromuscular diseases, cardiomyopathies, ataxias, optic nerve degradation, neurological indications and memory loss
Owner
- CHIESI FARMACEUTICI S.P.A., Parma (PR), IT
- CHIESI FARMACEUTICI S.P.A., Parma (PR), IT
Prosecution history
- 03 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Mar 2026 — SOU EXTENSION 1 GRANTED
- 02 Mar 2026 — SOU EXTENSION 1 FILED
- 02 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 30 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Aug 2025 — PUBLISHED FOR OPPOSITION
- 30 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 26 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 25 Jun 2025 — ASSIGNED TO EXAMINER
- 05 May 2025 — APPLICATION FILING RECEIPT MAILED
- 05 May 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 05 May 2025 — NEW APPLICATION ENTERED